Tags

Type your tag names separated by a space and hit enter

Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats.
Eur J Cardiothorac Surg. 2006 Jun; 29(6):902-7.EJ

Abstract

OBJECTIVE

Based on the findings that erythropoietin (EPO) has been proved to be a multiple functional cytokine to attenuate ischemia-reperfusion (I/R) injury in various organs such as brain, heart, and kidney in animals, this experiment was designed to evaluate the effect of pretreatment with recombined human erythropoietin (rhEPO) on I/R-induced lung injury.

METHODS

Left lungs of rats underwent 90 min of ischemia and then were reperfused for up to 2 h. Animals were randomly divided into three experimental groups as sham group, I/R group, and rhEPO + I/R group (a single dose of rhEPO was injected intraperitoneally 3000 U/kg 24 h prior to operation). Lung injury was evaluated according to semi-quantitative analysis of microscopic changes, tissue polymorphonuclear neutrophils (PMNs) accumulation (myeloperoxidase (MPO) activity), and pulmonary microvascular permeability (Evan's blue dying method). Peripheral arterial and venous blood samples were obtained for blood-gas analysis after 5 min occlusion of right lung hilus at the end of reperfusion. The serum concentration of tumor necrosis factor (TNF)-alpha was also measured by the method of enzyme-linked immunosorbent assay.

RESULTS

Histological injury scoring revealed significantly lessened lung alveolus edema and neutrophils infiltration in the rhEPO pretreated group compared with I/R group (p < 0.05). The rhEPO pretreated animals exhibited markedly decreased lung microvascular permeability (p < 0.05) and myeloperoxidase activity (p < 0.05). Blood-gas analysis demonstrated that the pretreated animals had significantly ameliorated pulmonary oxygenation function (p < 0.05). The serum concentration of tumor necrosis factor-alpha in rhEPO pretreated group was markedly decreased compared with that of I/R group (p < 0.05).

CONCLUSIONS

Pretreatment with rhEPO appears to attenuate I/R-induced lung injury. This function is partly related with the capacity that rhEPO inhibits the accumulation of polymorphonuclear neutrophils in lung tissue and decreases the systematic expression of tumor necrosis factor-alpha.

Authors+Show Affiliations

Department of Cardiothoracic Surgery, Jingling Hospital, Clinical Medicine School of Nanjing University, 305 Zhongshan East Road, Nanjing 210002, China. wu_haiwei@163.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16675226

Citation

Wu, Haiwei, et al. "Pretreatment With Recombined Human Erythropoietin Attenuates Ischemia-reperfusion-induced Lung Injury in Rats." European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery, vol. 29, no. 6, 2006, pp. 902-7.
Wu H, Ren B, Zhu J, et al. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg. 2006;29(6):902-7.
Wu, H., Ren, B., Zhu, J., Dong, G., Xu, B., Wang, C., Zheng, X., & Jing, H. (2006). Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery, 29(6), 902-7.
Wu H, et al. Pretreatment With Recombined Human Erythropoietin Attenuates Ischemia-reperfusion-induced Lung Injury in Rats. Eur J Cardiothorac Surg. 2006;29(6):902-7. PubMed PMID: 16675226.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. AU - Wu,Haiwei, AU - Ren,Binhui, AU - Zhu,Jiaquan, AU - Dong,Guohua, AU - Xu,Biao, AU - Wang,Changtian, AU - Zheng,Xiaogang, AU - Jing,Hua, Y1 - 2006/05/03/ PY - 2005/09/29/received PY - 2006/02/14/revised PY - 2006/02/20/accepted PY - 2006/5/6/pubmed PY - 2007/2/21/medline PY - 2006/5/6/entrez SP - 902 EP - 7 JF - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery JO - Eur J Cardiothorac Surg VL - 29 IS - 6 N2 - OBJECTIVE: Based on the findings that erythropoietin (EPO) has been proved to be a multiple functional cytokine to attenuate ischemia-reperfusion (I/R) injury in various organs such as brain, heart, and kidney in animals, this experiment was designed to evaluate the effect of pretreatment with recombined human erythropoietin (rhEPO) on I/R-induced lung injury. METHODS: Left lungs of rats underwent 90 min of ischemia and then were reperfused for up to 2 h. Animals were randomly divided into three experimental groups as sham group, I/R group, and rhEPO + I/R group (a single dose of rhEPO was injected intraperitoneally 3000 U/kg 24 h prior to operation). Lung injury was evaluated according to semi-quantitative analysis of microscopic changes, tissue polymorphonuclear neutrophils (PMNs) accumulation (myeloperoxidase (MPO) activity), and pulmonary microvascular permeability (Evan's blue dying method). Peripheral arterial and venous blood samples were obtained for blood-gas analysis after 5 min occlusion of right lung hilus at the end of reperfusion. The serum concentration of tumor necrosis factor (TNF)-alpha was also measured by the method of enzyme-linked immunosorbent assay. RESULTS: Histological injury scoring revealed significantly lessened lung alveolus edema and neutrophils infiltration in the rhEPO pretreated group compared with I/R group (p < 0.05). The rhEPO pretreated animals exhibited markedly decreased lung microvascular permeability (p < 0.05) and myeloperoxidase activity (p < 0.05). Blood-gas analysis demonstrated that the pretreated animals had significantly ameliorated pulmonary oxygenation function (p < 0.05). The serum concentration of tumor necrosis factor-alpha in rhEPO pretreated group was markedly decreased compared with that of I/R group (p < 0.05). CONCLUSIONS: Pretreatment with rhEPO appears to attenuate I/R-induced lung injury. This function is partly related with the capacity that rhEPO inhibits the accumulation of polymorphonuclear neutrophils in lung tissue and decreases the systematic expression of tumor necrosis factor-alpha. SN - 1010-7940 UR - https://www.unboundmedicine.com/medline/citation/16675226/Pretreatment_with_recombined_human_erythropoietin_attenuates_ischemia_reperfusion_induced_lung_injury_in_rats_ DB - PRIME DP - Unbound Medicine ER -